Daily MDOI Identifier Registry

Quality-Adjusted Life Expectancy by Socioeconomic Disadvantage and Remoteness Area: Population Norms for Australia

Performance of the EQ-5D-5L With Skin Irritation and Self-Confidence Bolt-On Items in Patients With Urticaria

cost-effectiveness analysis, dynamic pricing, life-cycle drug pricing, net price

Use of Real-World Evidence in Health Technology Reassessments Across 6 Health Technology Assessment Agencies

Drop the “M”: Minimally Important Difference and Change Are Not Independent Properties of an Instrument and Cannot Be Determined as a Single Value Using Statistical Methods

Quantifying Low-Value Care in Germany: An Observational Study Using Statutory Health Insurance Data From 2018 to 2021

A Person-Centered eHealth Intervention for Patients With Common Mental Disorders: Cost-Effectiveness Analysis Within a Randomized Controlled Trial

The Health Inequality Impact of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer in the United States: A Distributional Cost-Effectiveness Analysis

Costs and Health Outcomes in Economic Evaluations of Person-Centered Care: A Systematic Review

A Managed Access Protocol for Liraglutide for Weight Management: A Retrospective, Observational Study in Ireland

When Do Value-Based Contracts Add Value? Insights From Probabilistic Simulations

The Value of Positron Emission Tomography for Confirmation of Alzheimer’s Disease in the Era of Amyloid-Targeting Therapies

Understanding the Economic Value of Interventions Addressing Perinatal Mental Health Problems: A Literature Review and Methodological Considerations

Mapping the Landscape of Open Source Health Economic Models: A Systematic Database Review and Analysis: An ISPOR Special Interest Group Report

P3 Long Term Healthcare Costs and Utilization Among Patients with Non Obstructive Hypertrophic Cardiomyopathy

P2 Healthcare Resource Utilization (HCRU) and Cost among Patients with Metastatic Melanoma Receiving Nivolumab + Relatlimab (NIVO+RELA) or Nivolumab + Ipilimumab (NIVO+IPI) in the Optum Database

P1 Economic Burden of Recurrence among Patients with High-Risk Non-Muscle-Invasive Bladder Cancer who Received Bacillus Calmette-Guérin in the United States: A SEER-Medicare Study

Do Machine Learning Approaches Perform Better Than Regression Models in Mapping Studies? A Systematic Review

A Comparison of International Modeling Methods for Evaluating Health Economics of Colorectal Cancer Screening: A Systematic Review

An Acquired Taste: Latent Class Analysis to Compare Adolescent and Adult Preferences for EQ-5D-Y-3L Health States

Development and Testing of the Psychometric Properties of 20 Bolt-On Items for the EQ-5D-5L Across 31 Rare Diseases

Capturing the Additional Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists Beyond the Control of Traditional Risk Factors in People With Diabetes

Managing Uncomplicated Singleton Breech Pregnancy Using the OptiBreech Collaborative Care Pathway: Early Economic Model and Value of Information Analysis

The Price Effects of Biosimilars in the United States

Are Updated COVID-19 Vaccines Still Relevant for All Adult Age Groups? An Economic Evaluation of the Monovalent XBB.1.5 Vaccine in Australia

Early Cost-Effectiveness Analysis of Using Whole-Genome Sequencing for Patients With Castration-Resistant Prostate Cancer

Newer Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Improved Glycemic Control in US Adults With Type 2 Diabetes: A Population-Level Time Series Analysis

Public Health Supports Whole Health

Whole Health: A Global Perspective

Taking Health Economics and Outcomes Research Forward: Expanding the Definition of Value to Include Whole Health

What Does ‘Whole Health’ Really Mean for Health Economics and Outcomes Research?

Twenty-Four Years After the Launch of the EU Orphan Regulation: Analyzing Dutch Price Dynamics, Biosimilars, and Generics for Orphan Medicinal Products

Evolving Concept of Value in Health Economics and Outcomes Research: Emerging Tools for Innovation and Access to Cell and Gene Therapies for Rare Diseases

Rare Disease Policy in High-Income Countries: An Overview of Achievements, Challenges, and Solutions

Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions

How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report

How Do Bundled Payment Initiatives Account for Differences in Patient Risk Profiles? A Systematic Review

The Application of Time-Driven Activity-Based Costing in Oncology: A Systematic Review

A United Kingdom Value Set for the Weight-Specific Adolescent Instrument for Economic Evaluation

How Do Individuals Value Worse-Than-Dead EQ-5D-5L Health States in Composite Time Trade-Off Tasks? A Qualitative Study

A Value Set for EQ-5D-5L in the United Arab Emirates

A Comparison of the Performance of 6 Surrogacy Models, Including Weighted Linear Regression, Meta-Regression, and Bivariate Meta-Analysis

Role of Health Equity in Health Technology Assessment Processes: A Landscape Analysis of 13 Health Systems in Asia

Using Outcome Information During Consultation Yields Better Shared Decision Making, Better Patient Experiences, and More Positive Expectations: A Comparative Effectiveness Study

Age and Gender Differences in the Relationship Between Chronic Pain and Dementia Among Older Australians

Changes in Out-of-Pocket Drug Expenditures Among Medicare Beneficiaries With Dementia Under the Inflation Reduction Act: A Simulation Study

A New Approach for Assessing the Value of Informal Care in Alzheimer’s Disease

The Excess Direct Social Costs of Dementia-Related Neuropsychiatric Symptoms: A Regionwide Cohort Study Beyond Silos

Cost-Effectiveness of a Digitally Supported Care Management Program for Caregivers of People With Dementia

Indirect Costs of Alzheimer’s Disease: Unpaid Caregiver Burden and Patient Productivity Loss